RxDoctor Payments Data

Forrest Thompson, MD

Hematology · Shelby, NCNPI 1073551859

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $849 of the $1,152 with a category attached, or 73.6%. 11 manufacturers reported payments, led by Pacira Pharmaceuticals Incorporated at 41.9% of the total. Reporting peaked in 2019 at $583 and has fallen 54.9% since, to $263 in 2025. That places this record below the midpoint for hematology clinicians in NC, where the typical reported total is $12,876.

$1,152in general payments, 2019–2025

Across 17 payments — averaging $67.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$483
  • Amgen$195
  • Lilly USA, LLC$109
  • E.r. Squibb & Sons, L.L.C.$103
  • Johnson & Johnson$60
  • Adaptive Biotechnologies Corporation$57
  • plus $146 from 5 others

What the payments were for

  • Food & beverage$84974%
  • Education$30426%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,152 in reported general payments places this provider in the 30th percentile of 65 hematology providers in North Carolina.

See all hematology providers in North Carolina

Medicare billing

Part B allowed, 2024
$41,197
Medicare patients
134
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FruzaqlaFruquintinib16$368,979
RevlimidLenalidomide14$237,292
JakafiRuxolitinib Phosphate11$186,431
EliquisApixaban20$10,733
XareltoRivaroxaban12$6,244
Anastrozole140$1,298
Imatinib Mesylate12$869
Prochlorperazine Maleate78$837
Ondansetron Hcl96$831
Dexamethasone31$731
Tamoxifen Citrate23$422
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen23$382
Letrozole29$378
Oxycodone Hcl29$344
Olanzapine27$270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$60$6,24412 claims
Lilly USA, LLCOlanzapine$109$27027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 65 hematology providers in North Carolina.

Other hematology in Shelby

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →